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ABSTRACT
THE SYNERGISTIC EFFECT OF PULSED ELECTROMAGNETIC FIELDS
AND DEMINERALIZED BONE MATRIX ON THE OSTEOGENIC
DIFFERENTIATION OF MESENCHYMAL STEM CELLS
by
John Manocchio

Orthopaedic bone grafting continues to be a mainstay in the treatment of non unions and
other difficult to heal bone defects. Tissue engineering strategies have focused on
providing bone graft materials that are osteoconductive, osteoinductive and osteogenic in
order to achieve optimal bone healing. Furthermore, electrical stimulation technologies
such as pulsed electromagnetic fields (PEMF) have been used to enhance the
effectiveness of bone graft materials. PEMF has been shown to have a synergistic effect
with BMP-2 and it was hypothesized that PEMF would have the same effect with
demineralized bone matrix (DBM). In the present study human mesenchymal stem cells
(hMSCs) were seeded on DBM scaffolds in the presence of PEMF to determine if an
increased osteogenic response could be induced. hMSCs were harvested from scaffolds
at 5, 7, 14, and 21 days and osteogenic differentiation was assessed by testing for
expression of alkaline phosphatase (ALP) and osteocalcin. Results demonstrated that
PEMF was able to induce an increased osteogenic response throughout the 21 day
culture. ALP and osteocalcin were significantly increased for PEMF treated groups at the
earlier day 7 timepoint. DBM contains several osteoinductive growth factors and BMPs
including BMP-2. The synergistic response seen between PEMF and DBM was most
likely attributed to the osteoinductive factors found in DBM.
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CHAPTER 1
INTRODUCTION

1.1 Orthopaedic Bone Grafting
The enhancement of bone formation through the use of different bone graft
materials is an area of active research. Bone grafts have been used for various
orthopaedic applications including the reconstruction or replacement of skeletal defects,
augmenting fracture repairs, and the stimulation of arthrodeses following oncology
surgery, trauma, growth defects, and arthritis. ) Ideally, bone graft materials should fulfill
three areas necessary for optimal bone formation: osteoconduction, osteoinduction, and
osteogenecity. Osteoconduction is the ability of a bone graft to act as a scaffold for new
bone growth. These grafts should provide a three-dimensional structure that functions as
a trellis for osteoprogenitor cells to form new bone as well as support the ingrowth of
blood vessels and capillaries through angiogenesis. 2,3 Osteoinduction involves a cascade
of biological steps centering around chemotaxis, mitosis, and differentiation of
osteoprogenitor and mesenchymal stem cells (MSCs) in order to induce bone formation. 4
Bone grafts that are osteoinductive contain proteins and growth factors that induce bone
formation through the recruitment of osteoprogenitors and MSCs that undergo
osteoblastic differentiation. 3,5-7 Several factors and proteins have been investigated for
their osteoinductive potential, most notably bone morphogenic proteins (BMPs) and
transforming growth factor-beta (TGF-B). 3,8BMPsarelowmcuightprens
capable of initiating endochondral bone formation by stimulating osteoprogenitor cells
and by enhancing collagen synthesis. TGF- B is growth factor closely related to BMPs,
that is synthesized in many tissues including bone and is capable of stimulating bone
1
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formation. 1 ,8 Osteogenic grafts contain living bone forming cells such as osteoblasts or
cells capable of becoming bone forming cells such as osteoprogenitors and MSCs. An
ideal bone graft will be a suitable osteoconductive scaffold and also contain the necessary
osteoinductive growth factors and proteins to induce bone formation when coupled with
living osteogenic cells.
Autogenous cancellous bone graft contains all three of the aforementioned
characteristics and therefore has long been considered the gold standard for orthopaedic
bone grafting. 1,38,9Theorganiclmtxdorganichyptef
autogenous bone serves as an excellent osteoconductive scaffold for bone formation.'
Numerous osteoprogenitor and MSCs are contained within the periosteum lining as well
as bone marrow taken along with the graft making it osteogenic. 9 Finally, the autogenous
bone and adjacent clot contain a host of growth factors and proteins, including BMPs and
TGF-β making it osteoinductive. 8 It should be noted that cancellous bone is more
commonly used, but autogenous cortical bone is used on occasion for its superior
mechanical properties.' Additionally, autogenous grafts have the advantage of being
both immunocompatible and histocompatible because they are being harvested and
implanted within the same donor.
Although autograft is considered the gold standard, it does have several
disadvantages opening the door for the use of alternative bone graft materials.
Disadvantages of autograft include limited quantity and significant donor-site morbidity.
Donor-site morbidity rates related to autograft harvesting have been reported as high as
25% and include complications such as infections, pain, increased anesthesia time, and
increased operative blood loss.'" Recent efforts to reduce the morbidity associated with
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autogenous bone grafting have led to the development of several alternatives such as
allograft and synthetic ceramic grafts (Table 1.1). Additionally, certain orthopaedic
procedures may require a large volume of bone graft. In some cases the amount of
autograft that can be safely harvested is not sufficient, requiring the use of alternative
grafts as bone graft extenders.
Approximately 800,000 allografts are used in the USA each year. 12 Allograft
bone is typically harvested from a cadaveric donor, which is then frozen or processed to
be later implanted in a patient as a bone graft. Once harvested, allografts are either
frozen at -60°C or lyophilized to reduce degradation by enzymes, decrease
immunogenecity and preserve mechanical integrity. 1,8Sevraldifntoms
allograft bone are currently used in orthopaedics, including various sizes of chips,
granules, struts, segments, shafts, corticocancellous grafts and massive structural bone
allografts. 13 Allografts are osteoconductive and depending on the format and application,
can sometimes be used as a structural grafts. Processing of allogeneic bone is done
aseptically and is designed to remove all cellular components, including any osteogenic
cells. Although BMPs and growth factors naturally reside in bone, they are bound within
the mineral portion, significantly reducing the osteoinductive ability of allograft. 8 A
major concern with the use of allogeneic bone is the risk of disease transmission.
Although the risk is low, transmission of the hepatitis C virus and human
immunodeficiency virus (HIV) through allograft transplantation are both well
documented. 14,15Recntrdswihalogfbnevcusdorenig
procedures and tissue processing standards to cut down on the risk of disease
transmission.16
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Demineralized bone matrix (DBM) is a form of allograft in which the mineral
portion of bone is removed in order to expose osteoinductive proteins and growth factors.
Demineralization is achieved by treating bone with an acid in order to remove the mineral
hydroxyapatite portion, leaving non-collagenous proteins, growth factors and collagen.
DBM was first developed in the 1960's by Urist 17, who later went on to isolate BMPs in
DBM. The amount of BMPs and growth factors found in DBM varies among donors 18,
which has led to the development of several different assays used to quantify the
osteoinductive potential of DBM. Preliminary assays for osteoinductivity have focused
on the intramuscular implantation of DBM into athymic rats in order to test for ectopic
bone formation. 19 While this model has proven to be an accurate test for assessing DBM
osteoinductvity, additional assays have been sought out due to the relatively long
implantation time required. Recent work has focused on the development of in-vitro
assays, which can be correlated to the athymic rat model. Han et. al. 20 has developed an
in vitro assay looking at alkaline phosphatase expression of pluripotent myoblast C2C12
cells in the presence of DBM. The assay was correlated to the in vivo athymic rat model
and proved to be a less cumbersome model for assessing DBM osteoinductivity. DBM
has no cellular component and therefore is not osteogenic. Removal of the
hydroxyapatite mineral portion eliminates any structural properties of the allograft, but
the collagen that is left over is somewhat osteoconductive21 .
Ceramic bone graft materials provide users with a synthetic alternative to
autogenous and allogeneic grafts. Ceramic bone grafts are generally comprised of
calcium sulfates, calcium phosphates (hydroxyapatite), tricalcium phosphates (TCP),
calcium carbonates or combinations of different ceramics. 22-27 The grafts are
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manufactured commercially with no biological components and therefore cannot be
osteogenic or osteoinductive, but are osteoconductive. 1,82 Ceramicsboptle
and experience no adverse effects such as inflammation or foreign-body responses when
they are in a structural arrangement. 8,26,29,30 Ceramics can be sterilized via traditional
means 31 and because they are synthetic avoid the risk of disease transmission seen with
allograft. Ceramics can vary by crystallinity, porosity, mechanical strength and by their
resorption rates in the body. 28

Features / Properties
Bone Graft
Osteoconductive

Osteoinductive

Osteogenic

Autogenous
Bone

YES
Autogenous bone serves
as scaffold for new bone
growth

YES
Bone and adjacent
blood clot contains
growth factors including
TGF-β & BMPs8

YES
Periosteum lining and
entrapped bone marrow
contain MSCs and
osteoprogenitors 9

Allogenic
Bone

YES
Allogenic bone serves as
a scaffold for new bone
growth"

NO
Native BMPs and
growth factors are
trapped within mineral
portion8

NO
Processing of allogenic
bone destroys all
cellular components"

DBM

YES
Collagen portion may
act as a scaffold for new
bone growth21

YES
Demineralization allows
native BMPs and
growth factors todiffuse
d
out17

NO
Processing of allogenic
bone destroys all
cellular components1,8

Ceramics

YES
Ceramics serve as a
scaffold for new bone
growth1,8,28

NO
Ceramics are synthetic
materials, which do not
contain any native
biological components

NO
Ceramics are synthetic
materials, which do not
contain any native
biological components

Table 1.1 Current bone grafting options and their respective features / properties.
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1.3 Electrical Stimulation and Bone Healing
Electrical stimulation has been utilized in orthopaedics for several decades.
Dating back to the 1960s Bassett et. al. investigated the electrical response in living bone
when subjected to mechanical strain. 32-34 The investigation revealed that when hydrated
and deformed under mechanical strain, living bone became piezoelectrically charged. 32
Experiments also demonstrated that the polarity of the electric potential correlated to the
underlying physiological response in bone. Specifically, bone growth is associated with
negative electric potentials and bone resorption to positive electric potentials. 34 Based on
this initial work it was hypothesized that there was a link between the electrical fields
generated in bone and Wolf's Law. 32-36 Wolff's Law states that bone structure responds
to mechanical strain by remodeling to accommodate the applied forces. 37 Essentially
bone under stress will undergo bone formation and bone not under stress will experience
bone resorption. Subsequently, bone under stress exhibits a positive electric potential and
bone under no stress has a negative potential. These same principals have also been
shown to play a role physiologically during injury and bone growth. 37,38 Injury potentials
are electric fields generated by both soft and hard tissue in response to an injury. Growth
potentials are electric potentials produced by bone at sites of rapid bone growth such as
the growth plates during development.
Once a link between electric potentials and bone remodeling was established,
researchers sought out to investigate the response when electric potentials were induced
in bone. Initial pre clinical studies established that direct negative electric currents
induced from a cathode could increase the rate of bone formation and healing. 34,39-41 This
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work led to future clinical studies to see if the same concept could produce efficacious
and safe results in a clinical setting. One of the first clinical studies looking at electrical
stimulation for bone repair consisted of a multicenter study evaluating the use of direct
current to treat non-unions. 42 In total 175 patients were enrolled in the study and it was
determined that direct current achieved a healing rate (83.7%) that was comparable to the
current standard of autogenous bone grafting. The initial success of electrical stimulation
in bone healing has spawned continued research in the field, which has led to the
development of several different technologies that are used today. They include
inductive coupling devices such as pulsed electromagnetic fields and combined magnetic
fields, direct current, and capacitive coupling.

1.4 Pulsed Electromagnetic Fields
Inductive coupling stimulation consists of one or two external coils connected to a
signal generator and designed to deliver a magnetic field (Fig. 1.a). Inductive coupling
signals vary in types of pulse (single pulse or pulsed burst), frequency, amplitudes, and
time varying electromagnetic fields (EMFs) of 0.1 to 20G. 37 Pulsed electromagnetic field
(PEMF) technologies produce magnetic fields consisting of repetitive pulsed burst or
single pulsed signals (Fig. 1.b). Unlike DC technologies, which require implantation,
PEMF can be applied non-invasively over a fracture site in order to elicit a bone healing
response. Several pre-clinical animal studies have been performed in order to
substantiate the ability of PEMF to stimulate bone healing. PEMF has been shown to
stimulate healing rates of fractures in canines 43 , 44 and rats 45 , 46 , and non unions in
canines. 47 , 48 In a recent rabbit tibial distraction model PEMF was shown to accelerate
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the rate of bone formation. 49 Biomechanical analysis demonstrated that by 16 days postdistraction, the PEMF group had achieved a torsional strength equivalent to intact bone.
Similarly, PEMF resulted in a statistically significant increase in torsional stiffness when
compared to a control in a canine tibial osteotomy model. so Histomorphometric analyses
from the study revealed greater bone formation, increased mineral apposition rate, and
decreased porosity in the cortex adjacent to the osteotomy line for PEMF treated groups.
Finally, PEMF has shown increased benefit in terms of healing and graft encorporation
when used in combination with ceramic implants and scaffolds 5 1. s3 Histological and
biomechanical analysis of hydroxyapatite implants implanted into femoral cortical bone
of rabbits demonstrated that PEMF increased the direct contact of bone to the implant as
well as mechanical fixation of the implant. s2

20

,.

10 •

5 \

o

a.

b.

Figure 1.1 (a) Example of a commercial PEMF bone healing unitS4 , (b) Diagram of a

voltage waveform induced in cortical bone by single pulse PEMFs oriented along the
long axis of the bone 5s
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In addition to animal studies, many surgeons have performed clinical studies
aimed at evaluating PEMF in several different bone healing applications. PEMF has
been shown to be effective in treating scaphoid nonunions 56-58 , knee arthrodesis 59,
congenital pseudarthrosis of the tibia60,61, Jones fractures62, and osteonecrosis of the
femoral head.63-65 The bulk of the published clinical studies with PEMF center on the
treatment of non unions. Basset et. al. 66 evaluated the use of PEMF and autogenous bone
grafts to treat 83 patients with ununited fractures. Fractures included both lower and
upper extremities with the PEMF / autograft treatment resulting in a 90% fusion rate. In
1990 a multi-center double-blind clinical study was published investigating PEMF for the
treatment of tibial fracture delayed unions. 67 A total of 45 patients with fractures were
chosen for the study for their liability to delayed union due to the presence of moderate or
severe displacement, angulation or comminution or a compound lesion with moderate or
severe injury to skin and soft tissues. Patients were treated with a hard cast and either an
active or inactive PEMF unit. Radiographic assessment of the fractures at 12 weeks
revealed a statistically significant increase in the rate of fusion for patients treated with
PEMF. Patients that were actively treated with PEMF had a 45% fusion rate, while those
who did not receive active treatment had only a 12% healing rate. More recently, a
similar double-blind study evaluating PEMF for the treatment of tibial non-unions was
performed by Simonis et. a1. 68 A total of 34 patients with tibial non-unions were
randomly assigned to an active and non active PEMF group. Patients were assessed
clinically and radiographically for healing at 6 months post surgery. The PEMF group
had an overall fusion rate of 89% or 39% higher than that of the non active group.
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Until recently electrical stimulation technologies such as PEMF were considered a
"black box". Animal studies and clinical studies have demonstrated that PEMF can
increase the rate of bone healing, but recent in vitro studies have begun to look at the
mechanism of action behind PEMF. In vitro cultures of hMSCs on calcium phosphate
scaffolds have shown increased osteoblastic differentiation in response to PEMF. 69
Increased osteoblastic differentiation was only seen in cultures treated with BMP-2,
suggesting that PEMF induced surface-dependent changes making cells more responsive
to BMP-2 induced differentiation. In addition to increasing cell responsiveness to BMP2, PEMF has been shown to increase mRNA expression of several BMPs, including
BMP-2, 4, 5 and 7. 70-72 In a calvaria chick embryo model, PEMF was shown to enhance
BMP-2 mRNA levels by a 2.7 and 1.6 fold increase on days 15 and 17, respectively. 70
Similarly, PEMF resulted in a 1.6 fold increase of BMP-4 on day 15 and 1.5 fold increase
on day 17. In the same study PEMF was shown to enhance in vivo bone formation in
young embryos. The increased bone formation was correlated to the upregulated
expression of BMP-2 and 4 mRNA, suggesting that the upregulation of BMP-2 and 4
may mediate the bone inductive effect of PEMF. Yajima et. al. 71 used RTPCR to
examine PEMF treated human osteoblasts and their mRNA expression for various BMPs.
PEMF was shown to significantly enhance levels of BMP-2, 4, 5 and 7 in a time
dependent manner, with a maximum increase after 24 hours of treatment. Similar
experiments using RTPCR have indicated that PEMF exposure to rat calvarial osteoblasts
can lead to increased mRNA transcription of BMP-2 and 4. 73 PEMF has shown similar
effects in eliciting increased mRNA expression of TGF-13. 74 PEMF was able to
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moderately increase levels of TGF-B for a sustained period of time suggesting the ability
to generate temporal concentration gradients of growth factors to stimulate bone repair.
In vitro experiments with PEMF have also demonstrated changes at the bone cell
surface, which in turn affect mRNA and DNA synthesis of proteins and growth
factors. 37,75-82ExposuretPMFladincseumptakofbnedsit
insensitive to parathyroid hormone (PTH) 81,82byinhbtgcl-Adeos
Monophosphate (cAMP) 77 and PTH cell surface receptors. 79 Similarly, in vitro studies
have demonstrated increased calcium uptake of osteoblasts with PEMF. 78 Calcium
influences interactions between cell surface receptors, antibodies, hormones and
neurotransmitters. 75,80Boneclsurfait modlebnhaigtru
amplification of signal transduction pathways 76 that eventually effect mRNA and DNA
synthesis.

1.5 MSCs and Osteogenesis
Adult stem cells are resting cells present in small numbers in adult tissue with the
capacity for asymmetric cell division and self renewal.83 Biological signals and factors
capable of stimulating resting stem cells are responsible for inducing mitotic cell
divisions and morphogenic cell differentiations. MSCs are multipotent adult stem cells
capable of differentiating into cartilage, bone, tendon, ligament, marrow stroma and other
connective tissues within the mesodermic lineage(Fig. 1.2). 84 MSCs can be harvested
from several sources including, muscle, adipose, and placental tissue, but bone marrow
remains to be the most readably available source. 85-88 MSCs are present in concentrations
of approximately 36 per 1 million nucleated cells or approximately 2000 MSCs per 2 ml
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of bone marrow aspirate (BMA). 86 Characterization and quantification of MSCs is often
performed using in vitro colony forming unit (CFU) assays specifically looking for the
expression of fibroblasts89 or alkaline phosphatase 90 . Several different antibodies,
including CD105, CD44, CD166, CD29, CD90, and CD73 have also been identified as
markers that can be used to characterize MSCs. 91

Figure 1.2 MSCs are multipotent adult stem cells capable of differentiating into cartilage,
bone, tendon, ligament, marrow stroma and other connective tissues. 84
The progression from MSCs to a final phenotype such as bone is multistep
transition dependent upon both autocrine and paracrine regulation. 92 Bruder and Caplan
et. al. 93-97 have looked at the monoclonal antibodies generated against specific surface
antigens on differentiating osteogenic cells in order to define the various stages of
osteoblastic differentiation. Once committed to the osteogenic pathway, MSCs go
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through a series of cell differentiations marked by different surface antigens (Fig 1.3). 92
In vitro and in vivo phenotypes differ slightly, but MSCs generally start out as early
osteoprogenitors, which differentiate into pre then transitory osteoblasts and eventually
into dormant osteocytes.

In Vivo

Phenotypic Features

In Vitro

↓
Osteoprogenitor

No probes currently available

↓
Osteoprogenitor

↓Pre-Osteoblast

SB-1 (anti-Alkaline Phosphatase)-positive,
Non secretory, mitotic

↓Pre-Osteoblast

SB-1-, SB-3-positive
Non-secretory, mitotic

Transitory 1 Osteoblast

↓Transitory Osteoblast

SB-1-, SB-2-, SB-3-positive,
Non secretory, mitotic

↓Transitory Osteoblast

↓Secretory Osteoblast

SB-1-, SB-2-, SB-3-positive,
Secretory, non-dividing

↓Secretory Osteoblast

↓Osteocytic Osteoblast

SB-2-, SB-6-positive (SB-1-, SB-3-negative)
Secretory?, non-dividing

Osteocytic
Osteoblast
↓

Osteocyte

SB-5-positive (SB-1-, SB-2-, SB-3-negative)
Maintains bone physiology

Osteocyte

↓

Figure 1.3 MSCs express several different phenotypic features as they undergo
osteoblastic differentiation in vivo and in vitro.
Researchers have also looked into defining the mechanism of action for the
biological signals and factors responsible for inducing MSCs down the osteogenic
lineage. Members of the TGF-β super-family, which includes TGF-β1, BMPs, and other
growth and differentiation factors, are believed to play significant roles in stimulating the
osteogenic differentiation of MSCs. 98,99TGF-βproteins,cfalyBMPdTGF-β1,
have been studied extensively to determine how they interact with MSCs during
osteogenic differentiation. 99-106 TGF- β family members signal by binding activin

14
receptor-like kinases (ALKs), which initiate intracellular signaling through the
phosphorylation of specific Smad proteins. Once phorphorylated, Smad proteins move
from the cytoplasm to the nucleus where they go on to control transcription of certain
genes. 99 BMPs and TGF-Bs have been shown to upregulate Runx2 mRNA expression
levels when inducing osteoblastic differentiation of C2C1 2 cells (Fig. 1.4). 99,102 Runx2
has been shown to interact with BMP specific R-Smads, which are believed to be
important in inducing osteoblastic differentiation. 99,106 In humans, mutations in the
Runx2 gene have been linked to cleidocranial dysplasia (CCD), a disorder causing
delayed closure of sutures, small or absent clavicles, and tooth anomalies. 101,103
Similarly, Runx2 deficiencies in mice have been linked to a decrease in osteoblastic
proliferation.100 Finally, recent studies have demonstrated that BMPs induce the
expression of homeobox containing transcription factors Distal-less (Dlx-5), Msx-1, and
Msx-2, which have been shown to be important in osteogenesis. 104,105

Figure 1.4 Stimulatory or inhibitory effects of TGF-β super-family members on
differentiation of MSCs toward different lineages.99
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1.6 Bone Marrow Derived MSCs in Orthopaedics
Recent research in the field of orthopaedics has examined the use of bone marrow
derived MSCs for different bone grafting applications. Pre clinical research has centered
on evaluating the osteogenic potential of MSCs when combined with osteoconductive
scaffolds. 107-113 Bruder et. al. 107 performed a canine segmental defect model with
autologous MSCs loaded onto porous ceramic (f3-TCP/hydroxyapatite) cylinders.
Cylinders with and without cells were implanted into critical sized femoral defects and
evaluated radiographically and histologically at 16 weeks post implantation. Cylinders
loaded with MSCs had a radiographic union rate of 100% compared to 83% without
cells. Histomorphometry confirmed what was seen in the radiographs. Porous cylinders
loaded with MSCs were shown to have 39.9% new bone ingrowth, which was
statistically greater than the 24.0% ingrowth seen in cylinders with out MSCs. A sheep
tibial diaphyseal defect model was recently performed in order to evaluate isolated MSCs
combined with porous hydroxyapatite cylindrical scaffolds. 108 Scaffolds with and
without cells were implanted into the osseous defect and evaluated for healing 2 months
post implantation. Biomechanical analysis revealed higher stiffness values for the MSC
group compared to scaffolds without MSCs. Histomorphometry performed on explants
demonstrated a significantly higher volume of new bone formation for MSC loaded
implants (54.2%) compared to the scaffold without MSCs group (8.6%).
Although the amount of published clinical data for bone marrow derived MSCs is
low, there are a few key studies that highlight the efficacy of using MSCs and BMA in
orthopaedics. Connolly et. al. 114,115perfomdnthaliesuokngth
use of BMA as a substitute for autograft in the treatment of tibial nonunions. In the study
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a total of 20 patients were treated percutaneously with injections of BMA, resulting in a
90% healing rate. Healing time was reported at 7 months and was essentially equivalent
to healing times for autograft. 115-117 In a retrospective study for posterior spinal fusion in
adolescent idiopathic scoliosis BMA was combined with DBM and fusion was assessed
radiographically. 118 The BMA/DBM composite graft was able to achieve an 88.9%
fusion rate, which was equivalent to the fusion rate for autograft (87.5%). BMA has also
been shown to improve the effectiveness of xenogeneic bone for different bone grafting
procedures in pediatrics. 119 More recently Hernigou et. al. 120-123 has published data on the
use of concentrated BMA (cBMA) for the treatment of nonunions and avascular necrosis
(AVN). BMA was processed using a centrifugation device in order to concentrate the
number of MSCs available for treatment. Nonunion patients treated with cBMA had a
healing rate of 88% by an average of 12 weeks. 121 cBMA was shown to have
approximately a 4.2 times mean increase in MSCs over baseline BMA. The investigator
also reported that a minimum of 1500 MSCs/cc (3 X 10 5 MSCs total) was delivered to
those patients that healed; speculating that there is a minimum number of MSCs required
for the treatment of nonunions. Studies by the same author were performed evaluating
the use of cBMA to treat AVN of the femoral head 123 . When patients were treated at
stages I or II AVN, cBMA was able to achieve a success rate of 94%. Similarly, better
outcomes were seen in patients treated with a higher number of MSCs.
In vitro cultures have been used extensively to examine osteogenic differentiation
of MSCs. These cultures have relied on several different proteins and genes that have
been identified as markers of MSC osteoblastic differentiation 124. The initial proliferative
phase of MSCs in vitro is characterized by the expression of nuclear proteins H4 histone,
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c-fos, and c-jun. Differentiation follows with expression of Cbfal and then upregulation
of type 1 collagen, osteonectin and alkaline phosphatase (ALP). The final phase is linked
to extracellular mineralized matrix formation by secreting osteoblasts and can be
identified by the expression of osteocalcin, bone sialoprotein (BSP), and responsiveness
to 1,25-dihyroxy vitamin D and parathyroid hormone. 124-128 These markers are often
used to characterize the osteogenic response of MSCs cultured on various scaffolds in
order to determine optimal characteristics such as material, surface texture and porosity.
MSCs have been cultured in vitro on ceramic 129-132, polymer133,134, ceramic/polymer
composites 135 , Silk136,137, DBM 138-140 and collagen 141,142 scaffolds to ascertain their
osteoconductive and osteoinductive potential. Coralline hydroxyapatite (HA) scaffolds
with pore sizes of 200 and 500 μM were recently evaluated for the expansion and
differentiation of hMSCs in vitro. 130 Cells were harvested at days 1, 7, 14 and 21.
Scanning electron microscopy (SEM) performed on seeded scaffolds revealed that cells
coated both scaffolds on the surface and within the pores (Fig 1.5). ALP activity peaked
at day 14 for both scaffolds, but was significantly higher for the 200 μm pore scaffold.
mRNA expression of ALP and osteocalcin quantified using RTPCR saw similar results
with increased activity for the 200 pm pore size.
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Figure 1.5 Scanning electron micrographs of hMSCs cultured on the top surface of
coralline HA scaffolds with (a) 200 11m and (b) 500 11m pores 130
An in vitro study performed by Muller et. al. 129 compared scaffolds made of

calcium phosphate/silicon oxide (CPS) and hydroxyapatite to standard tissue culture
plastic. MSCs were harvested after 14 days and mRNA expression of seyeral osteogenic
f

markers including ALP, BSP, and osteocalcin were measured.

,mRN~

expression was

significantly higher for the scaffold groups in standard growth media, while expression
was the same for scaffolds and tissue culture plastic in osteoinductive media
supplemented with dexamethasone. Dexamethosone is used with in vitro cell cultures to
induce osteogenic differentiation of MSCs.

Typical osteoinductive media containing
\

small amounts of dexamethasone results in a significant increase in the expression of
I

osteogenic markers in vitrO. 143 Increased osteogenic differentiation of MSCs cultured on
CPS and hydroxyapatite scaffolds in standard growth media is indicative of an
osteoinductive response caused by the scaffolds.

DBM scaffolds have also been

evaluated with MSCs due to their ability to release naturally occurring growth factors and
BMPs.

In a recent study, AP levels were assessed for hMSCs cultured on partially
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demineralized cancellous bone scaffolds. 138 AP levels were significantly greater the
DBM scaffold group at days 7 and 14, with peak levels at day 7. SEM analysis revealed
that the majority of cells on the DBM scaffold had a cuboidal shape indicative of mature
osteoblasts, which contrasted to the fibrolast cell morphology seen on control scaffolds.

1.7 Bone Marrow Derived MSCs and PEMF
PEMF has been shown to be effective in stimulating bone healing through the
upregulation of several growth factors and BMPs. Previous work has investigated
PEMF's ability to stimulate osteoblastic differentiation of MSCs in vitro. 69,144-147 hMSCs
treated with PEMF and BMP-2 resulted in increased levels of osteocalcin at 24 days post
confluence. 69,146WithnesamudyMSCcltreonaiumphstdcn
the presence of PEMF and BMP-2 were shown to have increased levels of AP, TGF-β1
and prostaglandin E2 (PGE 2). In both cases PEMF and BMP-2 were shown to have a
synergistic effect on the osteoblastic differentiation of MSCs. Similar studies have
shown increased gene expression for MSCs cultured with weak, low-frequency PEMF. 145
EMFs have been shown to stimulate osteoblastic differentiation of mouse MSCs
(mMSC).144 Cylic AMP (cAMP) levels were also increased at days 1-3, indicating that
cAMP may be involved with EMF induced osteoblastic differentiation at early
timepoints. Finally, Moioli et al. 147 recently used PEMF with MSCs seeded on 3D
scaffolds in order to evaluate the technology with a more clinically relevant model.
HMSCs were cultured on UV-photo polymerized polyehtyleneglycol diacrylate
(PEGDA) hydrogels with and without PEMF and analyzed for expression of calcium and
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osteocalcin. PEMF was able to induce increased levels of both calcium and osteocalcin
at 2 weeks, however PEMF had no affect at 4 weeks.
Studies have shown that PEMF and BMP-2 can have a synergistic effect and
induce an increased level of osteogenic differentiation of MSCs. DBM is an
osteoconductive scaffold that has been shown to support cellular differentiation in vitro.
Furthermore, DBM is also an osteoinductive material that contains several growth factors
and BMPs including BMP-2. The present study will look to evaluate whether PEMF can
induce an elevated osteogenic response in hMSCs cultured in vitro on DBM scaffolds.

CHAPTER 2
METHODS

2.1 hMSC Isolation and Expansion
Human bone marrow aspirated from the iliac crests of a healthy adult donor
(Cambrex Corp, East Rutherford, NJ) was prepared according to previous protocols. 148
Briefly, the 25 mL marrow sample was washed with saline, followed by centrifugation
over a density gradient. The interface layer was removed, washed, and nucleated cell
counts were performed. Nucleated cells recovered from the density separation were
washed and plated in tissue culture flasks in growth medium (GM) consisting of
Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum
(FBS) and 1% antibiotic-antimycotic. Colony formation was monitored for a 14-17 day
period. When the tissue culture flasks were near confluent (-80%), the hMSCs were
passaged. At the end of the first passage, MSCs were enzymatically removed from the
culture flask using trypsin-EDTA and re-plated at a lower density for further expansion.
At the end of the second passage, MSCs were cryopreserved for later use.

2.2 Scaffold Preparation
Lyophilized human cortical allograft bone cylinders were obtained from an adult
donor who had successfully passed US Food and Drug Administration FDA and
American Association of Tissue Banks AATB screening procedures (University of
Miami Tissue Bank, Miami, FL). 149 The 5.0 mm (0.197 in) diameter cortical cylinders
were cut into 0.50 mm (0.019 in) discs using a rotary diamond coated saw (Buehler, Lake
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Bluff, IL). Demineralization was performed by a modification of the technique described
by Reddi and Huggins. 150 The cortical discs were demineralized in 0.5 N HCL for 24 hrs
(3 hr at room temperature, 21 hr at 4° C) with constant stirring, using 50 mL of HCL per
gram of cortical bone. The DBM scaffolds were then washed in purified water, pH 7.4
phosphate buffer, followed by a final water wash. The DBM scaffolds were then frozen
at - 20° C and lyophilized (Virtis, Gardiner, NY). DBM scaffolds were stored at -20° C
in order to preserve their osteoinductivity. 151 Deproteinized guanidine-extracted inactive
DBM scaffolds were generated using a modification of the technique described by Han et
al.20 DBM scaffolds were partially deproteinized and extracted with 10 ml of 4M
guanidine-HCL (50 mM Tris, pH 7.4) for 24 hr at room temperature with constant
agitation. The inactive DBM (dDBM) scaffolds were rinsed several times with distilled
water. Scaffolds were sterilized via an ethanol immersion for 20 minutes followed by 3
successive rinses in PBS totaling 50 minutes.
In vitro cultivation of hMSCs
Sterile DBM and dDBM scaffolds were placed in 96 well polypropylene nonadherent tissue culture plates (BD Biosciences, San Jose, CA). The cryopreserved
hMSCs were thawed and seeded at 15.15 x 10 3 cells/cm2 on the DBM and dDBM
scaffolds. hMSCs were also seeded at the same density in 96 well polystyrene tissue
culture (PTC) treated plates (BD Biosciences), which served as a control. Cells were
grown in GM for 2 days in a humidified 37°C/5% CO2 incubator to allow the cells to
reach confluency. At confluence GM was replaced with Osteogenic Media (OM)
consisting of GM supplemented with 1mM Dexamethasone (0.01% v/v), 1M B-
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Glycerophosphate (1.0% v/v) and 10mM ascorbic acid (0.5% v/v). Media was replaced
every 2nd or 3rd day until harvest at days 5, 7, 14 and 21 days post confluence.

2.3 Application of PEMF
To determine if pulsed electromagnetic fields (PEMF) could induce an osteogenic
response PEMF was applied via a Helmholtz coil (Biomet, Parsippany, NJ) specially
configured to two matched incubators. 69,152Metalshvindcubatorwe
replaced with acrylic shelves to reduce any potential interference of the electromagnetic
fields caused by current flow through the surrounding shelves. Prior to starting any
experiments with PEMF, background fields in the incubator and surrounding room were
measured. Background fields with the incubators off with and without the PEMF coils
placed inside were the same at less than 1 mG (rms). Similarly, fields were 4 mG (rms)
with incubator heaters and air circulators on. The PEMF signal that was used for this
experiment is the same signal used clinically for the treatment of fracture nonunions or
delayed fracture healing. The applied field consisted of 5-millisecond bursts of 20pulses,
repeating at 15 Hz. During each pulse, the magnetic field increased from 0 to 18 G within
200 microseconds and then decayed back to 0 G in 25 microseconds. The PEMF coils
were activated for 8 hours per day to simulate clinical use.

2.4 Cell Harvesting
hMSCs were harvested from the scaffolds and the amount of DNA was quantified
in order to determine the total number of cells. Briefly, the scaffolds were rinsed and the
cultured MSCs were lysed with 0.1% Triton-X. Scaffolds were immersed in 0.1%
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Triton-X for 1 hr and sonicated for 120s. PicoGreen ® dsDNA reagent (Invitrogen Corp.,
Carlsbad, CA) was used to quantify DNA in the cell lysate. PicoGreen dsDNA reagent is
an ultrasensitive fluorescent nucleic acid stain for quantifying double-stranded DNA in
solution. The amount of reagent bound DNA was quantified by reading absorbance on a
FLx800™ Multi-Detection Microplate Reader (BioTek Instruments Inc, Winooski, VT)
at 480 nm excitation / 520 nm emission using KC Junior software (BioTek Instruments
Inc, Winooski, VT). The amount of DNA was then used to calculate the total number of
cells harvested for each scaffold/group from a standard curve, which was created for each
timepoint.

2.5 Alkaline Phosphatase Activity
Harvested hMSCs were assayed for the presence of alkaline phosphatase (ALP) at
5, 7, 14 and 21 days post confluence with and without PEMF to assess osteogenic
differentiation. Cell lysate was assayed for ALP using p-nitrophenyl phosphate as a
substrate (Sigma-Aldrich Corp, St. Louis, MO). The presence of ALP was measured by
the hydrolysis of p-nitrophenylphosphate to p-nitrophenol using an absorbance plate
reader (Molecular Devices, Sunnyvale, CA) at 410 nm with SoftMax Pro Software
(Molecular Devices, Sunnyvale, CA).

2.6 Osteocalcin Activity
Harvested hMSCs were assayed for the expression of Osteocalcin at 7, 14 and 21
days post confluence in order to assess osteogenic differentiation. Cell lysate was
assayed for intact osteocalcin using an EIA kit (Biomedical Technologies Inc, Stoughton,
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MA). Monoclonal antibodies directed toward the amino and carboxy terminal regions of
intact osteocalcin were utilized and absorbance was measured at 450 nm.

2.7 Scanning Electron Microscopy
Scanning electron microscopy (SEM) was performed on scaffolds at 1, 7 and 21
days to assess cell morphology and distribution. Scaffolds were rinsed and fixed in
paraformaldehyde — glutaraldehyde solution (Karnovsky fixative) followed by a
dehydration using a series of immersions in increasing concentrations of ethanol.
Dehydrated fixed scaffolds were then left to dry in Freon for 24 hours. Fixed scaffolds
were carbon coated and viewed with an Electro Scan 2020 SEM (Electroscan,
Wilmington, MA).

2.8 Statistical Analysis
All assays were performed with an n = 4 for each data point. Results in graphs
are presented as mean ± standard error of the mean (SE). Results were analyzed using a
one-way ANOVA (Fisher's, individual error rate). Statistically significant values were
defined as p ≤ 0.05. All statistical analyses were performed using Microsoft Excel and
Minitab version 15.1.0.0 (Minitab Inc., State College, PA).

...

CHAPTER 3
RESULTS

3.1 Cell Harvest

hMSCs were harvested from dDBM and DBM scaffolds and PTC controls at 5, 7,
14 and 21 days post confluence. An average of 10.84 X 103 ± 4.41, 13.32 X 103 ± 3.15,

and 16.50 X 103 ± 1.77 cells were harvested at day 5 from the control, dDBM and DBM
scaffolds, respectively (Fig. 3.1). The total number of cells harvested from each scaffold
remained relatively consistent throughout the culture, with trends showing a slight
increase for all groups on day 14. PEMF had no effect on cell proliferation for any of the
scaffold groups (Fig. 3.2). The complete dsDNA assay results for PTC controls and
dDBM scaffolds can be found in Appendix A.
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Figure 3.1 Total hMSCs harvested from different scaffolds and surfaces.
hMSCs were grown in osteogenic media and were not treated with PEMF.
Number of cells was determined using a DNA assay. Values are Mean ± SE.
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Figure 3.2 Total hMSCs harvested from dDBM & DBM scaffolds in OM
with (+) or without (.) PEMF. Number of cells was detennined using a
DNA assay. Values are Mean ± SE.

3.2 Alkaline Phosphatase Activity
I

hMSCs harvested from scaffolds were assessed for ALP ,activit,Y at 5, 7, 14, and
21 days post confluence.

ALP is often used as a marker to assess osteogenic

differentiation of MSCs in vitro. ALP expression increased significantly for hMSCs on
both dDBM and DBM scaffolds with and without PEMF during the 21 day culture (Fig.

,

3.3: dDBM, PEMF(-) p = 0.003; dDBM PEMF(+) p = 0.004; DBM, PEMF(-) P = 0.009;
DBM PEMF(+) p = 0.009).

Cells harvested from PTC contTols had
no significant
I

increase in ALP expression. No significant differences in ALP expression were revealed
upon comparing perfonnance 'of the different scaffolds. For both scaffold groups ALP
expression increased steadily for the first 14 days and then significantly increased
between days 14 and 21 days when exposed to PEMF (dDBM p = 0.004; DBM p =
0.050). Results indicated that there was a general trend where PEMF resulted in higher

..
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mean ALP expression for hMSCs on dDBM (53%) and DBM (95%) scaffolds throughout
the culture, but the increase over baseline groups without PEMF was only shown to be
significant earlier timepoints. For hMSCs cultured on dDBM scaffolds PEMF resulted in
a significant increase of ALP initially at day 5 (78%, p
14 (110%,p

=

=

0.004) and then peaked at day

0.005) (Fig. 3.4). hMSCs cultured on DBM scaffolds with PEMF saw a

slight increase of ALP expression at day 5 (65%) and then peaked at day 7 (%257),
although the increase was only significant at the latter timepoint (p

=

0.050). Complete

ALP results for both scaffolds and the PTC control can be found in Appendix B.
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Figure 3.4 PEMF effect on alkaline phosphatase activity for hMSCs
harvested from dDBM and DBM scaffolds in OM. Values are Mean.

3.3 Osteocalciu Activity
,
hMSCs harvested from scaffolds were assessed for osteocalcin ~ctivity at 5,7, 14,
f

and 21 days post confluence. Osteocalcin is used as an osteogenic marker in vitro and is
typically expressed by MSCs during the latter stages of osteogenic differentiation.
Osteocalcin levels remained relatively level for hMSCs on both dDBM and DBM
scaffolds with and without PEMF during the 21 day culture (Fig. 3.5). Cells harvested
\

from PTC controls had no significant increase in osteocalcin expression. No significant
differences in osteocalcin expression were revealed upon comparing performance of the
different scaffolds. PEMF did result in a general trend of increased mean osteocalcin
expression for hMSCs seeded on dDBM (%44) and DBM (34%) scaffolds throughout the
21 day culture, but this increase was not significant. hMSCs on dDBM scaffolds had no
PEMF induced osteocalcin increase initially at day 7, but then their was a slight increase
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for days 14 and 21 (%75) (Fig. 3.6). However, the PEMF induced response was only
significant for day 7 when hMSCs were cultured in GM. For hMSCs on DBM scaffolds
PEMF resulted in a sporadic increase of osteocalcin that dropped slightly at day 14 (9%)
and was higher at days 7 and 21 (-45%). Similarly, the PEMF induced response was
only significant for day 7 when hMSCs were cultured on DBM scaffolds in GM.
Complete osteocalcin results for both scaffolds and the PTC control can be found in
Appendix C.
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Figure 3.5 Osteoca1cin activity for hMSCs harvested from dDBM and DBM
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Figure 3.6 PEMF effect on osteocalcin activity for hMSCs harvested from
dDBM and DBM scaffolds in OM. Values are Mean.
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3.4 SEM Analysis

I

.

f

Qualitative SEM analysis was performed on scaffolds to assess cell morphology
and extracellular matrix (ECM) deposition at 0, 7, and 21 days .post confluence. Both
DBM and dDBM scaffold SEM images had visible lacunae ranging from 20 - 70 Ilm in
diameter (Fig. 3.7). No differences in cell morphology, distribution, or ECM deposition
were seen between scaffolds with and without exposure to PEMF at any timepoint. At
I

day 1 hMSCs were present on the surface of both scaffolds (Fig. 3.8.a -' b). At day 7
ECM deposition had initiated and it was difficult to identify' cells on the surface of the
scaffolds, but cells could be seen both inside and spanning individual lacunae (Fig. 3.8.c d). No visible cells were located on day 21 scaffolds. Considerable ECM deposition had
taken place by day 21 with extensive matrix formation both on the surface and covering
the lacunae of the scaffolds.
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Figure 3.7 SEM micrographs of (a) DBM and (b) dDBM scaffolds with visible lacunae
on the surfaces.
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•

Figure 3.8 SEM micrographs of scaffolds cultivated with hMSCs: (a) DBM, Day 0, (b)
dDBM, Day 0, (c) DBM, Day 7, (d) dDB¥, .Day 7, (e) DBM, Day 21, (f) dDBM, Day
21. White arrows in (a - d) indicate celh.ilai- focal adhesions . . (e - f) ECM deposition
covering surface and spanning lacunae of scaffolds.

CHAPTER 4
DISCUSSION

Orthopaedic bone grafting continues to be a mainstay in the treatment of non
unions and other difficult to heal bone defects. Tissue engineering strategies for bone
formation have focused on the use of bone graft materials that have osteoconductive,
osteoinductive and osteogenic properties. Traditional autogenous cancellous bone grafts
remain to be the gold standard in orthopaedics, but synthetic and allogenic grafts have
garnered attention due to the increased morbidity associated with harvesting autograft.
To date, none of the current alternative grafts collectively possess osteoconductive,
osteoinductive and osteogenic properties (Table 1.1). Recent trends have shifted towards
the use of composite grafts made up of two or more different bone grafts in order to
provide all three of the necessary components for optimal bone formation. Additionally,
the use of electrical stimulation technologies such as PEMF have been used to further
stimulate the effectiveness of bone graft materials. In the present study, MSCs were
cultured on DBM scaffolds in the presence of PEMF to determine if an increased
osteogenic response could be induced in vitro.
Studies have demonstrated that DBM scaffolds can be used to support osteogenic
differentiation of MSCs in vitro. 138-140,153 SEM micrographs of the dDBM and DBM
scaffolds used in this study revealed that cells could be detected on the surface of
scaffolds starting at day 0. ECM deposition had taken place by day 7, and by day 21
extensive ECM had formed covering the entire surface of the scaffolds including the
lacunae.
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In the present study, ALP expression for MSCs cultured on DBM scaffolds
increased slightly through days 5 and 7 and then rapidly increased on day 14. Exposure
to PEMF resulted in a similar response where there was a slight elevation in ALP
expression early on, but then a rapid increase on day 21. ALP expression for MSCs on
dDBM scaffolds with and without PEMF also saw a slight rise in ALP early on and then
a rapid increase at later timepoints. For all groups, ALP activity was greater in cultures
with OM compared to GM. ALP is expressed by MSCs at early to intermediate stages
(days 7 — 10) of osteoblastic differentiation in vitro. 130,154,155 This was seen for hMSCs
cultured on TCP controls where ALP peaked at day 7. Interestingly, ALP activity for
MSCs harvested from both scaffolds in this study were highest at day 21, suggesting that
differentiation was occurring later than what is typically seen in vitro. Osteocalcin
expression of MSCs cultured on DBM scaffolds remained relatively level through day
21, but saw a slight increase on day 21 in the presence of PEMF. Osteocalcin levels
associated with dDBM scaffolds both with and without PEMF also remained consistent
throughout the 21 day culture. Osteocalcin is a bone-specific gene that is often expressed
by cells in the latter stages of differentiation (days 14 — 21). 130,154 In general, osteocalcin
expression did not peak for MSCs cultivated on scaffolds in the 21 day culture, indicating
that the cells were still in the early to intermediate stages of differentiation at day 21.
ALP results suggested the same, in that ALP levels typically peaked at later timepoints.
Previous work by Mauney et. al. 139 has looked at the osteogenic differentiation of MSCs
cultured on DBM scaffolds in vitro. Although differentiation was only assessed at days 7
and 14, ALP levels were relatively the same for both days. Based on the results from
the present study one can speculate that differentiation was still in the earliest stages and
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that an increase in ALP activity would have occurred at later timepoints such as day 21.
Similarly, in vitro cultures with BMP-2 conditioned media have also demonstrated
increasing ALP for MSCs through 21 days. 69, 146 BMPs and growth factors may therefore
have a delayed effect on MSCs in vitro, where osteogenic differentiation is induced at
later timepoints such as 21 days. Hence, ALP activity was highest at day 21 and
osteocalcin remained the same for cells harvested from scaffolds in the present study.
Although no quantitative analysis was performed to determine cellular
distribution on the scaffolds used in this study, cells were observed both on the surface
and inside the lacunae of the scaffolds. The DBM and dDBM scaffolds were derived
from allograft cortical bone because of its inherent low porosity, as opposed to trabecullar
bone, which is known for its larger and more prevalent porosity. It was originally
thought that the cells would remain on the surface of the scaffolds, making this a 2-D in
vitro model. This was not the case and it was evident early on that cells were able to
locate the lacunae and make there way in, indicating that the scaffolds were in fact
supporting 3-D differentiation of cells. Cultivation of cells in a 3-D versus 2-D in vitro
environment have been shown to have differences in cellular proliferation and
differentiation 139, and thus may explain the differences in ALP and osteocalcin activity
seen between the 3-D scaffold groups and 2-D TCP controls in this study.
The use of in vitro cultures to evaluate both DBM scaffolds and PEMF for
osteogenic differentiation of MSCs is limited. To date much of the data on the
mechanism of action behind PEMF suggests a strong relation between BMPs and PEMF
induced osteogenesis. Recent work has shown that PEMF can elicit an increased
osteogenic response when BMP-2 conditioned media is used.69,146 PEMF has also been
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shown to upregulate BMP mRNA expression in vitro. 71,73,74DBM is a known
osteoinductive material that contains BMP-2 among other growth factors and it was
hypothesized that MSCs cultured on DBM scaffolds in the presence of PEMF would
elicit an increased osteogenic response. MSCs cultivated from DBM scaffolds in the
presence of PEMF exhibited increased levels of ALP throughout the 21 day culture. ALP
levels for MSCs seeded on DBM scaffolds in the presence of PEMF had an overall mean
increase of 95%. The greatest response was seen at day 7 where PEMF resulted in a
257% mean increase of ALP activity. Similar results were seen with osteocalcin
expression, although not as pronounced. PEMF resulted in an overall mean increase of
34% in osteocalcin expression, with the highest increase also seen on day 7 (54%).
Despite the consistent elevation in ALP and osteocalcin, the increase was only shown to
be significant at day 7 for both markers (ALP/OM, osteocalcin/GM). These results differ
from other studies examining the effect of PEMF on MSC osteogenic differentiation.
Specifically, PEMF was not able to induce such a robust response as previously reported
by Schwartz et. al. 146 who saw significant PEMF induced increases in ALP expression on
days 12 through 24. The elevated response due to PEMF was only seen in MSCs
cultured in OM supplemented with BMP-2 (40 ng/ml). While DBM is known to contain
several growth factors including BMP-2, the amount of growth factors is relatively low.
Specifically, DBM has been shown to contain the following: BMP-2 = 21.4 +/- 12.0 ng/g
DBM, BMP-4 = 5.45 +/- 2.04 ng/g DBM, and BMP-7 = 84.1 +/- 34.4 ng/g DBM. 18
Assuming a 100% diffusion of proteins from the DBM scaffolds (0.075 g DBM), the
amount of BMP-2 released would still be significantly lower than a continuous treatment
of BMP-2 (4.0 ng BMP-2/100 1A1 media) with every media change. Within the same
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study, calcium phosphate (CP) scaffolds were also used. CP comprises the mineral
portion of bone (hydroxyapatite) and is an excellent osteoconductive scaffold. Studies
looking at osteogenic differentiation on different allograft scaffolds have seen
significantly higher ALP expression with fully mineralized bone than DBM in certain
donor lines of MSCs. 139 Based on those results, CP may serve as a better scaffold for
osteogenic differentiation in vitro. This is not entirely surprising because PEMF has been
shown to increase calcium uptake of cells in vitro. 81 ,82 Furthermore, PEMF may have a
synergistic effect with BMP-2 in combination with CP. Recent experiments have also
used 3D PEGDA hydrogels to investigate the effect of PEMF on MSC osteogenic
differentiation. 147 Results revealed elevated levels of osteocalcin and calcium for MSCs
exposed to PEMF at 2 weeks. In this case PEMF was able to induce an increased
osteogenic response without BMP-2, suggesting that the PEGDA hydrogels may have
interacted with PEMF. Such was not the case in the present study where PEMF had no
effect on hMSCs cultivated on tissue culture treated polystyrene. Although the response
to PEMF was not as dramatic compared to previous studies, the response was greater for
the DBM and dDBM groups, suggesting that the scaffold may play a significant role in
PEMF induced osteogenic differentiation.
Deproteinized dDBM scaffolds were used to confirm whether a synergistic effect
between DBM derived BMPs and PEMF existed. dDBM scaffolds were created by
performing a guanidine extraction in order to remove all the native proteins found in
DBM. Interestingly, hMSCs cultivated from dDBM scaffolds saw a mean increase in
ALP of 53% in response to PEMF, with a peak increase of 110% at day 14. Osteocalcin
expression was elevated by 44% in response to PEMF, with a peak increase at day 21
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(77%). MSCs cultured on DBM scaffolds did not express increased osteogenic activity
when compared to dDBM scaffolds with or without PEMF. These results were surprising
in that despite the deproteinization (1) PEMF had a slight positive effect on ALP and
osteocalcin activity for the dDBM scaffolds and (2) there was no significant difference in
ALP or osteocalcin expression between the two scaffolds. The guanidine extraction
method used for deproteinization in this study has been validated to extract the BMPs and
growth factors found in DBM. 20 C2C12 cells were cultured in the presence of DBM and
dDBM powder for 2 days and assessed for ALP expression. The study demonstrated an
increased response in ALP for cells cultured in the presence of DBM when compared to
dDBM powder. The particle size for DBM powder is small in volume (200 -500 μm)156
and therefore has a relatively high surface to volume (S/V) ratio. Assuming the powder
is spherical with an average diameter of 350 μm, DBM powder would have a S/V ratio of
8.56. The scaffolds used in this study had a significantly lower S/V ratio (3.07), which
would most likely limit the rate of diffusion and in turn the reaction kinetics for the
guanidine extraction. Therefore, it is possible that the dDBM scaffolds used in this study
were not completely deproteinized and contained residual BMPs and growth factors.
This would explain why a response to PEMF was seen for dDBM groups and why there
was no difference in ALP or ostecalcin activity between the two scaffolds. Similarly, the
same argument can also be applied to the rate of elution for BMPs and growth factors.
Simply, the smaller S/V ratio would limit the elution rate of proteins out of the scaffold
when compared to DBM powder. Previous studies have compared ALP activity for fully
and partially demineralized bone scaffolds. 139 ALP activity between the two scaffolds
remained the same, despite the fully demineralized scaffolds having more DBM and
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accessible BMPs and growth factors. Surprisingly, histology performed on the same
scaffolds implanted in vivo revealed higher bone formation scores for the DBM groups.
In vivo the release of BMPs and growth factors is aided by the enzymatic digestion and
osteoclastic resorption of DBM. The in vitro release of growth factors and BMPs is
dependent upon diffusion and therefore much less efficient, hence the disparity between
the in vivo and in vitro results.

CHAPTER 5
CONCLUSION

DBM scaffolds were used to determine if PEMF could induce an osteogenic
response for hMSCs in vitro. While PEMF did result in increased osteogenic activity, the
response was only significant for the early day 7 timepoint. Surprisingly, PEMF was also
shown to have a positive effect on dDBM scaffolds, but again the response was only seen
early on and was not as dramatic as previous studies evaluating PEMF with BMP-2
conditioned media. This can be attributed to several factors including the limited elution
of BMPs and growth factors from the scaffolds in vitro. This is not to say that DBM is
not as effective as previously thought. In vivo, the release of proteins is aided by
enzymatic digestion and osteoclastic resorption of DBM. Furthermore, DBM powder has
been shown to be an effective osteoinductive material both in vivo and in vitro, partly
because of its high S/V ratio. Scaffolds made of DBM powder held together with a
carrier may prove to be more effective in this vitro model. Future in vitro studies
evaluating PEMF and DBM scaffolds should look to simulate in vivo conditions more
closely, but results from this study were promising. Despite limited levels and elution of
BMPs, PEMF was still able to induce an osteogenic response, suggesting that the scaffold
and PEMF had a synergistic effect. Additional work with PEMF and DBM should focus
on in vivo studies to evaluate MSCs seeded on DBM scaffolds in the presence of PEMF
to determine efficacy in a more clinically relevant model.
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APPENDIX A - DNA ASSAY RESULTS
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Figure A.I Total hMSCs harvested from polystyrene tissue culture treated
plates in GM/OM with (+) and without (-) PEMF . Values are Mean ± SE.
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Figure A.2 Total hMSCs harvested from dDBM scaffolds in GMiOM
With (+) and without (-) PEMF. Values are Mean ± SE.

42

43

Cell Number - DBM Scaffold
35000
30000
~

OJ

25000

..c

E 20000

::s

o GM, PEMF(-)

z 15000

Oi
u

mGM, PEMF(+)

10000

iB OM, PEMF(-)

5000

III OM, PEMF(+)

0
5

7

14

21

Days (Post Confluence)

Figure A.3 Total hMSCs harvested from DBM scaffolds in GMiOM
With (+) and without (-) PEMF. Values are Mean ± SE.

I

(

APPENDIX B - ALKALINE PHOSPHATASE ASSAY RESULTS
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APPENDIX C - OSTEOCALCIN ACTIVITY
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Figure C.l Osteocalcin activity for hMSCs harvested from polystyrene
tissue culture treated plates in GMiOM with (+) and without (-) PEMF.
Values are Mean ± SE. P<O.OS, (#) timepoint v. previous timepoint.
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Figure C.2 Osteocalcin activity for hMSCs harvested from dDBM scaffolds
in GMiOM with (+) and without (-) PEMF. Values are Mean ± SE.
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